<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Management of claudication due to peripheral artery disease</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Management of claudication due to peripheral artery disease</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Management of claudication due to peripheral artery disease</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark G Davies, MD, PhD, MBA, FACS, FACC</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Denis L Clement, MD, PhD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John F Eidt, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Joseph L Mills, Sr, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Mark A Creager, MD, FAHA, FACC, MSVM</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Kathryn A Collins, MD, PhD, FACS</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 31, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Claudication (derived from the Latin word for limp) is defined as a reproducible discomfort of a defined group of muscles that is induced by exercise and relieved with rest. Once a patient is diagnosed with claudication due to peripheral artery disease (PAD), the approach to treatment needs to account for the severity of symptoms, the patient's daily activities and limitations, their age and medical comorbidities, and location and extent of disease. </p><p>The general management of the patient with claudication due to PAD is reviewed. The indications for intervention (endovascular, surgical) and techniques for lower extremity revascularization and their outcomes are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/15220.html" rel="external">"Approach to revascularization for claudication due to peripheral artery disease"</a> and  <a class="medical medical_review" href="/z/d/html/15217.html" rel="external">"Endovascular techniques for lower extremity revascularization"</a> and  <a class="medical medical_review" href="/z/d/html/15194.html" rel="external">"Lower extremity surgical bypass techniques"</a>.)</p><p>The management of exertional leg pain from arterial obstruction due to other diseases (eg, aneurysm thrombosis, embolism), arterial compression (eg, popliteal entrapment syndrome), or musculoskeletal disorders (eg, lumbar spine stenosis, adductor bursitis, spine or hip osteoarthritis) differs from PAD and is discussed in separate topic reviews. The differential diagnosis of these is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/8208.html" rel="external">"Clinical features and diagnosis of lower extremity peripheral artery disease", section on 'Differential diagnosis of PAD'</a>.)</p><p class="headingAnchor" id="H50931105"><span class="h1">APPROACH TO MANAGEMENT</span><span class="headingEndMark"> — </span>For most patients with claudication, we recommend an initial medical treatment regimen that includes cardiovascular risk reduction, including smoking cessation, exercise therapy (for those who can participate), and possibly pharmacologic therapy  (<a class="graphic graphic_algorithm graphicRef109428" href="/z/d/graphic/109428.html" rel="external">algorithm 1</a>), rather than initial revascularization [<a href="#rid1">1-3</a>]. Medical management that includes exercise therapy is effective and does not have the potential risks associated with complications of intervention, which can worsen symptoms or lead to amputation [<a href="#rid4">4</a>]. It also more cost-effective as a first-line treatment for claudication [<a href="#rid5">5,6</a>]. Improvement in walking capacity is generally better for supervised compared with nonsupervised exercise therapy, and exercise therapy compared with available pharmacologic therapies. Periodic reevaluation of symptoms will determine the effectiveness of these therapies for a particular patient. A selected subset of patients may be appropriate for initial revascularization. (See <a class="local">'Referral for possible intervention'</a> below and  <a class="medical medical_review" href="/z/d/html/15220.html" rel="external">"Approach to revascularization for claudication due to peripheral artery disease", section on 'Clinical criteria for revascularization'</a>.)</p><p class="headingAnchor" id="H1202062168"><span class="h2">Risk for progression and risk modification</span><span class="headingEndMark"> — </span>Although PAD and its severity is an important marker for cardiovascular risk, symptoms of claudication are associated with an overall low risk of progression to limb-threatening lower extremity ischemia. Natural history studies show that most patients with claudication remain stable, particularly if they stop smoking. The following limb outcomes at five years demonstrate the low risk of progression for patients with lower extremity claudication [<a href="#rid3">3,7</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Stable claudication: 70 to 80 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Worsening claudication: 10 to 20 percent</p><p class="bulletIndent1"><span class="glyph">●</span>Progression to critical limb ischemia: 1 to 2 percent</p><p></p><p>Risk factors for atherosclerosis and strategies to reduce the future risk for cardiovascular events are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/15210.html" rel="external">"Epidemiology, risk factors, and natural history of lower extremity peripheral artery disease", section on 'Epidemiology and risk factors'</a> and  <a class="medical medical_review" href="/z/d/html/95282.html" rel="external">"Overview of lower extremity peripheral artery disease", section on 'Risk factor modification'</a>.) </p><p class="headingAnchor" id="H2383272633"><span class="h2">Evidence supporting initial medical therapy</span><span class="headingEndMark"> — </span>Systematic reviews of trials performed between 1996 and 2015 (including the CLEVER and ERASE trials [<a href="#rid8">8-10</a>]) comparing treatment strategies (supervised exercise therapy, intervention [angioplasty/stenting], medical therapy, or combinations) support an initial conservative approach in patients with stable claudication [<a href="#rid11">11,12</a>]. </p><p>In some but not all trials, a combination of percutaneous transluminal angioplasty (PTA) and exercise (supervised exercise therapy or exercise advice) produced the greatest initial changes in walking distance compared with exercise alone or PTA alone, and a handful of trials also reported significant quality-of-life improvements for those undergoing intervention [<a href="#rid8">8-10,13-17</a>]. However, these and other meta-analyses report diminishing benefits of revascularizations in the longer term [<a href="#rid18">18</a>].</p><p class="bulletIndent1"><span class="glyph">●</span>Among trials comparing supervised exercise therapy alone with intervention alone (five in each meta-analysis), there were no differences in exercise capacity (maximum walking distance, pain-free walking distance) or differences in future revascularization or amputation [<a href="#rid5">5,8,9,19-28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among trials comparing intervention with no specific treatment (except advice to exercise) maximum walking distance and pain-free walking distances were improved for the intervention group [<a href="#rid11">11</a>]. However, long-term follow-up in two studies did not show any differences [<a href="#rid23">23,24,29-32</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among trials that compared supervised exercise therapy alone with patients who underwent supervised exercise therapy combined with endovascular therapy, there were no clear differences between groups for maximum walking distance (standard mean difference [SMD] 0.26, 95% CI -0.13 to 0.64) or pain-free walking distance (SMD 0.33, 95% CI -0.26 to 0.93) [<a href="#rid5">5,10,21,26,27,33</a>]. In one of the trials that had longer follow-up, PTA, supervised exercise, or combined treatment were compared in 178 patients with claudication related to femoropopliteal disease [<a href="#rid21">21</a>]. With long-term follow-up (mean 5.2 years, range 3.8 to 7.4 years), those who had angioplasty (with or without exercise) had a significantly higher ankle-brachial index (ABI), but no significant differences were observed between the groups for treadmill walking distances, restenosis rates, new ipsilateral and contralateral lesions on duplex imaging, or quality-of-life outcomes [<a href="#rid26">26</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial, which compared intervention plus pharmacotherapy (<a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a>) with pharmacotherapy alone, intervention provided a benefit for maximum walking distance (SMD 0.38, 95% CI 0.08-0.68) and a moderate effect on pain-free walking distance (SMD 0.63, 95% CI 0.33-0.94) in favor of combination therapy [<a href="#rid17">17</a>]. </p><p></p><p>Functional improvements with a medical therapy regimen that includes exercise therapy tend to be more durable compared with endovascular intervention as an initial treatment strategy and are associated with less morbidity and mortality [<a href="#rid19">19-21</a>]. In a review of a national database including over 50,000 patients with intermittent claudication, primary treatments included supervised exercise therapy in 72 percent, endovascular treatment in 22 percent, and surgery in 6 percent. Patients who underwent primary endovascular or open surgical treatment had a higher risk of subsequent revascularization compared with supervised exercise therapy (endovascular: hazard ratio [HR] 1.44, 95% CI 1.37-1.51; open surgery: HR 1.45, 95% CI 1.34-1.57), and a higher mortality risk (endovascular: HR 1.38, 95% CI 1.29-1.48; open surgery HR 1.49, 95% CI 1.34-1.65). </p><p>In a later network meta-analysis, the mean differences in walking distance compared with baseline for short (&lt;1 year) and intermediate (1 to &lt;2 years) follow-up were greatest for supervised exercise therapy and supervised exercise therapy combined with endovascular treatment [<a href="#rid18">18</a>]. At long-term (&gt;2 years) follow-up, none of the tested treatments improved mean walking distance compared with controls. Similarly, in the IRONIC trial [<a href="#rid34">34</a>], which randomly assigned patients with mild-to-severe intermittent claudication to either revascularization plus best medical therapy and structured exercise therapy (revascularization) or best medical therapy and structured exercise therapy (nonrevascularization), no long-term improvement in health-related quality-of-life or walking capacity was seen for a revascularization compared with a nonrevascularization strategy. Revascularization was also not a cost-effective treatment option from a payer/health care point of view. In a separate trial that included a cost analysis also found no significant differences in functional outcomes between supervised exercise therapy, PTA, or a combination of supervised exercise therapy and PTA [<a href="#rid5">5</a>]. However, in this study, supervised exercise was more cost-effective as a first-line treatment for claudication. </p><p class="headingAnchor" id="H87308846"><span class="h1">SMOKING CESSATION</span><span class="headingEndMark"> — </span>We agree with the guideline recommendations regarding smoking cessation, in general, and in particular in patients with peripheral artery disease [<a href="#rid3">3,7,35-39</a>]. (See  <a class="medical medical_review" href="/z/d/html/16634.html" rel="external">"Overview of smoking cessation management in adults"</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span>All patients should be strongly advised to stop smoking by their physicians.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients should be offered pharmacotherapy, behavior modification, referral to a smoking cessation program, and counseling.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>All patients who are smokers or former smokers should be asked about the status of tobacco use at every visit.</p><p></p><p>Continued smoking restricts improvements in pain-free walking symptoms that might otherwise be seen with an exercise program [<a href="#rid40">40</a>], and with continued smoking, patients are also less likely to benefit from the pharmacologic agents discussed below. (See <a class="local">'Pharmacologic therapy to improve walking'</a> below.)</p><p>It is not clear whether cessation of cigarette smoking reduces the severity of claudication symptoms. In one study that looked at pain-free and total walking distance outcomes, smoking cessation led to a nonsignificant increase in total walking distance [<a href="#rid41">41</a>]. However, smoking cessation does appear to favorably alter the progression of PAD [<a href="#rid42">42-44</a>]. As an example, a review of 343 patients with claudication compared the clinical outcomes among those who quit smoking (39 patients) with those who continued to smoke (304 patients) [<a href="#rid44">44</a>]. Rest pain, a sign of limb-threatening ischemia, did not occur in patients who stopped smoking but developed in 16 percent of patients who continued to smoke. </p><p class="headingAnchor" id="H9"><span class="h1">EXERCISE THERAPY</span><span class="headingEndMark"> — </span>We recommend an exercise therapy program as part of the initial treatment regimen for patients with claudication based upon randomized trials demonstrating significant improvements in walking parameters for those who participate  (<a class="graphic graphic_algorithm graphicRef109428" href="/z/d/graphic/109428.html" rel="external">algorithm 1</a>) [<a href="#rid45">45,46</a>]. (See <a class="local">'Evidence supporting initial medical therapy'</a> above.)</p><p>Patients should be referred to a claudication exercise rehabilitation program, if possible, depending upon insurance coverage or personal resources. Home and community-based therapy are also effective for improving walking tolerance but are less effective than supervised exercise and are associated with a high dropout rate, underscoring the need for ongoing psychological support [<a href="#rid47">47-54</a>]. [<a href="#rid55">55</a>]</p><p>There are several mechanisms by which exercise training may improve claudication, although the available data are insufficient to make conclusions regarding the relative importance of each [<a href="#rid56">56-63</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>Increased calf blood flow </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improved endothelial function increases endothelial-dependent dilation </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced local inflammation (induced by muscle ischemia) by decreasing free radicals </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvements in muscle architecture</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improvements in muscle mitochondrial capacity</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improved muscular strength and endurance, and increased exercise pain tolerance </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Induction of vascular angiogenesis </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Improved mitochondrial and muscle function and muscle metabolism </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Reduced red cell aggregation and blood viscosity </p><p></p><p>Many studies have evaluated the effects of an exercise rehabilitation program for reducing the symptoms of claudication. A systematic review and meta-analysis (Cochrane) identified 27 trials that compared exercise with usual care or placebo [<a href="#rid64">64</a>]. In a meta-analysis of nine of the trials (391 participants), exercise significantly improved pain-free walking distance (mean difference [MD] 82.1 meters [269 feet]; 95% CI 71.7-92.5) and maximum walking distance (MD 120.4 meters [395 feet]; 95% CI 50.8-189.9). Exercise did not improve the ankle-brachial index. In a Bayesian network meta-analysis comparing the change in physical activity between baseline and follow-up treatments, supervised exercise therapy improved daily physical activity levels in patients with intermittent claudication [<a href="#rid65">65</a>]. Home-based exercise therapy appeared to have a similar benefit, while invasive treatment failed to significantly improve physical activity compared with control.</p><p>Although not well studied, exercise ability may be related to survival in PAD patients. In one meta-analysis, a shorter maximum walking distance was associated with increased five-year cardiovascular and all-cause mortality [<a href="#rid66">66,67</a>]. However, in the Cochrane review above [<a href="#rid64">64</a>], a meta-analysis of five trials found no effect for exercise on mortality, when compared with placebo or usual care (relative risk [RR] 0.92, 95% CI 0.39-2.17).</p><p>A systematic review identified favorable effects for supervised exercise therapy on modifiable cardiovascular risk factors in patients with intermittent claudication [<a href="#rid68">68</a>]. In the short term, systolic and diastolic blood pressure were improved, but no effect was seen in midterm studies; however, supervised exercise therapy contributed to lowering low-density lipoprotein cholesterol and total cholesterol levels. No effect for supervised exercise therapy was identified for heart rate, triglycerides, high-density lipoprotein cholesterol, glucose, glycated hemoglobin, body weight, body mass index, or cigarette smoking. </p><p class="headingAnchor" id="H1543323845"><span class="h2">Types and prescription</span><span class="headingEndMark"> — </span>Patients with peripheral vascular disease have impaired muscle strength and walking ability, resulting in progressive functional impairment and poorer quality of life. Leg strength is linearly correlated with lower extremity ankle-brachial index and with functional performance in patients with peripheral artery disease [<a href="#rid69">69</a>]. </p><p>Independent of the mode of delivery, all exercise programs should be progressive and individually prescribed where possible, considering disease severity, comorbidities, and initial exercise capacity [<a href="#rid70">70</a>]. All patients should aim to accumulate at least 30 min of aerobic activity, at least three times a week, for at least three months, ideally in the form of walking exercise to near-maximal claudication pain. The benefits of exercise diminish when exercise training stops. </p><p class="headingAnchor" id="H1516192079"><span class="h3">Treadmill exercise</span><span class="headingEndMark"> — </span>Despite the evidence of benefit, issues remain concerning the optimal regimen for exercise rehabilitation [<a href="#rid71">71,72</a>]. In general, exercise should be performed for a minimum of 45 to 60 minutes at least three times per week for a minimum of 12 weeks. During each session, an exercise level that is of sufficient intensity to elicit claudication should be achieved. Guidelines from the American College of Cardiology/American Heart Association (ACC/AHA) recommend initiation of exercise at an intensity that induces onset of claudication within 3 to 5 minutes and moderate to moderately severe claudication within 8 to 10 minutes [<a href="#rid73">73,74</a>]. (See <a class="local">'High-intensity versus low-intensity exercise'</a> below.)</p><p>Supervised exercise programs generally consist of a series of sessions lasting 45 to 60 minutes per session, using a treadmill. Including warm-up and cool-down periods of 5 to 10 minutes each, the initial session usually includes 35 minutes of intermittent walking. Walking is then increased by five minutes each session until 50 minutes of intermittent walking can be accomplished. Ideally, the patient attends at least three sessions per week, with a program length greater than three months [<a href="#rid7">7</a>]. Each session is supervised on a one-to-one basis by an exercise physiologist, physical therapist, or nurse. The supervisor monitors the patient's claudication threshold and other cardiovascular parameters. During supervised exercise, the development of new arrhythmias, symptoms that might suggest angina, or the continued inability of the patient to progress to an adequate level of exercise require physician review and examination of the patient. Most patients who eventually respond to a supervised exercise protocol can expect improvement within two months, but the benefits of exercise diminish if exercise training stops. </p><p class="headingAnchor" id="H10576104"><span class="h3">Alternative modes of exercise</span><span class="headingEndMark"> — </span>Although most trials have used lower extremity exercise (eg, treadmill or walking), other forms of exercise have been investigated for improving walking performance in patients with PAD [<a href="#rid75">75-84</a>]. These include upper-arm ergometry [<a href="#rid81">81,85-87</a>], cycling [<a href="#rid75">75</a>], and resistance/strength training [<a href="#rid82">82-84,88-92</a>]. For patients with claudication who cannot participate in a walking program, we suggest using an alternative strategy for exercise therapy, which can be beneficial for improving walking ability and functional status. However, in a systematic review, there was no clear difference comparing alternative exercise modes and supervised walking exercise for improving the maximum and pain‐free walking distance in patients with intermittent claudication [<a href="#rid93">93</a>]. </p><p>A systematic review and meta-analysis included ten trials comparing supervised exercise therapy with alternative modes of exercise training (eg, cycling, upper extremity exercise) or combinations of modes in patients with claudication [<a href="#rid93">93</a>]. Among the included trials, there were no significant differences for maximum walking distance or pain-free walking distance. </p><p>Among the alternative modalities, lower extremity resistance training may be the most promising. Resistance training using loads approaching 90 percent of one-repetition maximum (RM) induces vasodilation and reactive hyperemia and improves several clinical parameters (eg, maximal strength, VO<sub>2 </sub>max) without evidence of adverse effects such as worsening pain [<a href="#rid82">82-84,88-92</a>]. In an early trial that included 29 patients with disabling claudication, 12 weeks of strength training were less effective compared with 12 weeks for supervised treadmill exercise [<a href="#rid84">84</a>]. A later trial randomly assigned 156 patients with PAD (with and without claudication) to a six-month program of either supervised treadmill exercise or lower extremity resistance training, or to a control group [<a href="#rid82">82</a>]. Lower extremity resistance training intervention did not improve six-minute walking distance in PAD participants, but it did improve maximal treadmill walking time and quality-of-life measures, particularly stair climbing ability. This mode of exercise may be useful for those who are unable to participate in a walking program. Suggestions for muscle strengthening in older adults are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/16524.html" rel="external">"Physical activity and exercise in older adults", section on 'Muscle strengthening'</a>.) </p><p class="headingAnchor" id="H1751309952"><span class="h3">High-intensity versus low-intensity exercise</span><span class="headingEndMark"> — </span>The optimal intensity of exercise is uncertain. Walking exercise that induces ischemic leg symptoms has been referred to as high-intensity walking exercise compared with low-intensity walking exercise, which does not induce ischemic symptoms.</p><p>While high-intensity walking exercise is recommended [<a href="#rid2">2,73,74</a>], many, but not all, studies have suggested that exercise treadmill training should be performed to near-maximal claudication levels [<a href="#rid94">94,95</a>]. However, few trials have directly compared the relative benefits or harms of walking to different levels of claudication. In an early meta-analysis, use of near-maximal pain during training as a claudication pain endpoint was an independent predictor of improvement in walking distance [<a href="#rid96">96</a>]. A later meta-analysis reported similar outcomes for participants who walked to a mild claudication level compared with those who walked to a severe level of claudication [<a href="#rid94">94</a>]. A small trial comparing high- versus low-intensity exercise also reported similar outcomes [<a href="#rid97">97</a>]. However, a later larger trial, the Low-Intensity Exercise Intervention in PAD (LITE) trial, reported a benefit for high-intensity exercise. In the LITE trial, 305 patients with claudication were randomly assigned to unsupervised, remotely monitored walking exercise that was either low-intensity or high-intensity, or to a non-exercise control for 12 months [<a href="#rid98">98</a>]. The patients using high-intensity exercise benefited the most. The within-group mean change in six-minute walking distance at 12 months was significantly increased for the high-intensity compared with low-intensity group (34.5 versus -6.4 meters). The mean group change was similar for the low-intensity group and the nonexercise group. Adverse events rates were low and similar between the groups. Based on these trials, we recommend an exercise program in which the patient is counseled to walk to the point that claudication symptoms occur, then to rest; when the pain is relieved, to walk again, repeating this cycle for 45 to 60 minutes. We support guidelines from the ACC/AHA guidelines that recommend that supervised exercise protocols should be initiated at an intensity that induces onset of claudication within 3 to 5 minutes and moderate to moderately severe claudication within 8 to 10 minutes.</p><p class="headingAnchor" id="H2529830312"><span class="h3">Supervised versus unsupervised exercise</span><span class="headingEndMark"> — </span>Although we suggest supervised exercise therapy where available, unsupervised exercise (particularly a structured program) may be the only option when access to supervised programs is limited by transportation, availability, insurance coverage, or other cost-related issues [<a href="#rid8">8,99-103</a>]. The relative effectiveness of supervised versus unsupervised exercise has been evaluated in systematic reviews [<a href="#rid47">47,95,100,104-106</a>]. Walking is the dominant form of exercise training for each group. Supervised exercise therapy showed a greater improvement in maximal treadmill walking distance compared with unsupervised exercise therapy; however, there were no significant effects on the measured quality-of-life parameters between the study groups. </p><p>Active feedback has also been incorporated into supervised training regimens [<a href="#rid40">40,107</a>]. A multicenter trial in a community setting with physical therapists staffing outpatient vascular surgery clinics randomly assigned 304 patients to supervised exercise training with accelerometer feedback, supervised training without feedback, or unsupervised walking at home following instruction [<a href="#rid107">107</a>]. Supervised exercise training significantly improved walking distance (360 meters with feedback, 310 meters without feedback) compared with unsupervised walking at home (110 meters)  (<a class="graphic graphic_figure graphicRef57368" href="/z/d/graphic/57368.html" rel="external">figure 1</a>). In this study, improvements in quality-of-life measures corresponded to improvements in walking distance. In a trial that compared home-based exercise intervention using a wearable activity monitor and coaching over the phone, there were no significant improvements in walking distance [<a href="#rid108">108</a>]. </p><p class="headingAnchor" id="H86506333"><span class="h2">CMS coverage</span><span class="headingEndMark"> — </span>The Centers for Medicare &amp; Medicaid Services (CMS) in the United States has determined that the evidence is sufficient to cover supervised exercise therapy for beneficiaries with intermittent claudication (IC) for the treatment of symptomatic PAD. The summary for this decision is as follows [<a href="#rid109">109</a>].</p><p>Up to 36 sessions over a 12-week period are covered if all of the following components of a supervised exercise therapy program are met. The supervised exercise therapy program must:</p><p class="bulletIndent1"><span class="glyph">●</span>Consist of sessions lasting 30 to 60 minutes comprising a therapeutic exercise-training program for PAD in patients with claudication;</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Be conducted in a hospital outpatient setting or a physician's office; </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Be delivered by qualified auxiliary personnel necessary to ensure benefits exceed harms, and who are trained in exercise therapy for PAD; and </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Be under the direct supervision of a physician, physician assistant, or nurse practitioner/clinical nurse specialist who must be trained in both basic and advanced life support techniques.</p><p></p><p>Beneficiaries must have a face-to-face visit with the physician responsible for PAD treatment to obtain the referral for supervised exercise therapy. At this visit, the beneficiary must receive information regarding cardiovascular disease and PAD risk factor reduction, which could include education, counseling, behavioral interventions, and outcome assessments.</p><p>Medicare Administrative Contractors have the discretion to cover supervised exercise therapy beyond 36 sessions over 12 weeks and may cover an additional 36 sessions over an extended period of time. A second referral is required for these additional sessions. There is a zero-value professional relative value unit (RVU) component associated with this new code and a minimal facility RVU component. The presence of the code does not mean it will be reimbursed or covered by federal, state, and nongovernmental payers.</p><p>Supervised exercise therapy is non-covered for beneficiaries with absolute contraindications to exercise as determined by their primary physician. </p><p class="headingAnchor" id="H11"><span class="h1">PHARMACOLOGIC THERAPY TO IMPROVE WALKING</span><span class="headingEndMark"> — </span>Specific pharmacologic therapy of claudication is aimed at improving symptoms and increasing walking distance in patients with lifestyle-limiting claudication, particularly if risk modification and exercise therapy have not been effective and revascularization cannot be offered or is declined by the patient [<a href="#rid2">2,7,37,38,110,111</a>]. For patients with lifestyle-limiting claudication, we suggest a therapeutic trial (three to six months) of either <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> or naftidrofuryl depending upon availability  (<a class="graphic graphic_algorithm graphicRef109428" href="/z/d/graphic/109428.html" rel="external">algorithm 1</a>). Naftidrofuryl has fewer side effects than cilostazol and, where available, can be tried first. If the effect is not sufficient, then changing to cilostazol is warranted. Naftidrofuryl is not available in the United States, and cilostazol may have limited availability outside the United States. </p><p>A number of other pharmacologic agents have been evaluated, but firm evidence of decreased pain with ambulation or increased walking distance (total or pain-free) is available for only <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> and naftidrofuryl. Statin therapy may also improve walking parameters. Other pharmacologic therapies aimed at reducing progression and complications associated with atherosclerotic disease are also discussed above. (See <a class="local">'Risk for progression and risk modification'</a> above.)</p><p>For other agents, a benefit has not been firmly established. It is important to note that pharmacologic therapy is less beneficial for those who do not quit smoking and do not participate in an exercise therapy program. (See <a class="local">'Smoking cessation'</a> above and <a class="local">'Exercise therapy'</a> above.)</p><p class="headingAnchor" id="H50931993"><span class="h2">Beneficial</span></p><p class="headingAnchor" id="H451547835"><span class="h3">Cilostazol</span><span class="headingEndMark"> — </span><a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">Cilostazol</a> is a phosphodiesterase inhibitor that suppresses platelet aggregation and is a direct arterial vasodilator, but its mechanism of action for improving walking distance in patients with claudication is not known [<a href="#rid112">112</a>]. Benefits to therapy are noted as early as four weeks after the initiation of therapy [<a href="#rid113">113,114</a>]. Cilostazol (100 mg twice daily) should be taken a half hour before or two hours after eating, because high-fat meals markedly increase absorption. Several drugs such as <a class="drug drug_general" data-topicid="9365" href="/z/d/drug information/9365.html" rel="external">diltiazem</a> and <a class="drug drug_general" data-topicid="9718" href="/z/d/drug information/9718.html" rel="external">omeprazole</a>, as well as grapefruit juice, can increase serum concentrations of cilostazol if taken concurrently [<a href="#rid115">115</a>]. Cilostazol may be taken safely with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> and/or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> without an additional increase in bleeding time [<a href="#rid116">116</a>]. Side effects for cilostazol noted in clinical studies included headache, loose and soft stools, diarrhea, dizziness, and palpitations [<a href="#rid113">113,117-119</a>]. Nonsustained ventricular tachycardia has been reported. Because other oral phosphodiesterase inhibitors used for inotropic therapy have caused increased mortality in patients with advanced heart failure, cilostazol is contraindicated in heart failure of any severity [<a href="#rid115">115</a>]. (See  <a class="medical medical_review" href="/z/d/html/3488.html" rel="external">"Inotropic agents in heart failure with reduced ejection fraction", section on 'Intravenous phosphodiesterase-3 inhibitors'</a>.)</p><p>The efficacy of <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> has been demonstrated in several meta-analyses [<a href="#rid120">120-123</a>]. In one of these, 2702 patients with stable moderate-to-severe claudication who received cilostazol (100 mg cilostazol twice daily for 12 to 24 weeks) were compared with placebo [<a href="#rid120">120</a>]. Significantly greater increases in maximal walking distances (MWDs) and pain-free walking distances (PFWDs) were seen in patients treated with cilostazol (MWD: 67 versus 50 percent increase from baseline, PFWD: 40 versus 22 percent). In a later systematic review that compared cilostazol with naftidrofuryl and <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>, cilostazol appeared to be slightly less effective than naftidrofuryl but more effective than pentoxifylline [<a href="#rid122">122</a>]. </p><p class="headingAnchor" id="H50933361"><span class="h3">Naftidrofuryl</span><span class="headingEndMark"> — </span>Naftidrofuryl (600 mg daily orally), which is currently available in Europe, can be used for treatment of claudication [<a href="#rid38">38</a>]. Naftidrofuryl has fewer side effects than <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> and, where available, can be tried first. If the effect is not sufficient, then changing to cilostazol is warranted.</p><p>Naftidrofuryl is a 5-hydroxytryptamine-2-receptor antagonist [<a href="#rid124">124-126</a>]. The mechanisms of action of this drug are unclear, but it is thought to promote glucose uptake and increase adenosine triphosphate levels. Systematic reviews have consistently identified significant and clinically meaningful improvements in walking distance after initiation of naftidrofuryl therapy [<a href="#rid41">41,122,127</a>]. The later of these performed a network meta-analysis and found that the percentage change from baseline for mean walking distance increased 60 percent compared with placebo, and pain-free walking distance increased 49 percent compared with placebo, differences that were greater for naftidrofuryl compared with <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> or <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a> [<a href="#rid122">122</a>].</p><p class="headingAnchor" id="H200381319"><span class="h2">Benefit not firmly established</span></p><p class="headingAnchor" id="H3660404618"><span class="h3">Medical therapies</span><span class="headingEndMark"> — </span>Medical therapies with benefits that <strong>have not been firmly established</strong> <strong>for improving claudication symptoms</strong> include statin therapy, antiplatelet agents, and <a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">pentoxifylline</a>. Nevertheless, statin therapy and antiplatelet therapy are recommended to reduce the risk for future cardiovascular events. (See <a class="local">'Risk for progression and risk modification'</a> above.)</p><p class="bulletIndent1"><span class="glyph">●</span>Statin therapy – A number of trials in patients with hyperlipidemia and coronary heart disease or PAD have evaluated the effects of lipid-lowering trials on the natural history of PAD [<a href="#rid128">128-131</a>]. Initial studies, performed before the availability of statins, showed regression or less progression of femoral atherosclerosis with lipid-lowering therapy [<a href="#rid132">132-136</a>], and a lower incidence of claudication and limb-threatening ischemia in patients with hyperlipidemia who were treated with surgery [<a href="#rid137">137</a>]. A 2007 Cochrane meta-analysis that specifically evaluated patients with lower extremity PAD concluded that lipid-lowering therapy reduced disease progression (as measured by arteriography) and may help alleviate symptoms and improve total walking distance and pain-free walking distance [<a href="#rid128">128</a>]. There was no effect on ankle-brachial index. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Antiplatelet agents – The preponderance of data on currently available antiplatelet agents indicate only a modest improvement or no improvement in claudication symptoms can be expected and that a significant benefit may not be seen with <a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> alone. These agents are also associated with negative side effects that limit their usefulness, especially compared with the therapies discussed above (<a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> and naftidrofuryl). Thus, the main indication for antiplatelet therapy remains the secondary prevention of coronary heart disease and stroke. (See <a class="local">'Beneficial'</a> above.)</p><p></p><p class="bulletIndent1">Among three trials identified in a systematic review evaluating walking distance [<a href="#rid138">138-140</a>], antiplatelet therapy significantly improved pain-free walking distance compared with placebo (mean difference 78 feet) [<a href="#rid141">141</a>]. In five trials, the risk of revascularization was also reduced by antiplatelet treatment compared with placebo (RR 0.65, 95% CI 0.43-0.97) [<a href="#rid142">142-146</a>]. These trials used <a class="drug drug_general" data-topicid="9996" href="/z/d/drug information/9996.html" rel="external">ticlopidine</a>, picotamide, or indobufen. These agents are not available in the United States but may be available internationally. Ticlopidine is associated with a substantially increased risk of leukopenia and thrombocytopenia, requiring close hematologic monitoring for at least three months. Other potential side effects of antiplatelet therapy include bleeding, dyspepsia, diarrhea, nausea, anorexia, rash, purpura, and dizziness. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> – The available data indicate that the benefit of pentoxifylline is marginal, particularly in light of more effective therapies such as <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> and naftidrofuryl, which are discussed above [<a href="#rid122">122</a>]. (See <a class="local">'Beneficial'</a> above.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9757" href="/z/d/drug information/9757.html" rel="external">Pentoxifylline</a> is a rheologic modifier approved for use in the United States for the symptomatic relief of claudication. Its putative mechanisms of action include increased deformability of red blood cells and blood viscosity, decreases in fibrinogen concentration, and reduced platelet adhesiveness. Studies investigating the efficacy of pentoxifylline have yielded conflicting results [<a href="#rid147">147-152</a>], leading to variable recommendations for its use by various society guidelines [<a href="#rid7">7,37,38,111</a>]. One meta-analysis found that pentoxifylline improved walking distance by 29 meters compared with placebo [<a href="#rid151">151</a>]. In a later systematic review, the percentage improvement in total walking distance for pentoxifylline over placebo ranged from 1.2 to 156 percent, and for pain-free walking distance the difference ranged from -34 to 74 percent [<a href="#rid152">152</a>]. Improvements in walking distances associated with pentoxifylline are generally substantially less than those achieved with a supervised exercise program [<a href="#rid153">153</a>] or <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> [<a href="#rid154">154</a>]. </p><p></p><p class="headingAnchor" id="H2909417178"><span class="h3">Compression therapy</span><span class="headingEndMark"> — </span>Intermittent mechanical (non-pneumatic) calf compression has been used to treat claudication. In a trial that randomly assigned 30 patients with stable claudication to active intermittent compression claudication distance or medical therapy alone, absolute claudication distance (42 percent) and postexercise (but not resting) ankle-brachial index percent at one month were significantly increased [<a href="#rid155">155</a>]. Treatment effects were maintained or further improved after cessation of therapy at three months; postexercise ankle-brachial index was maintained. </p><p class="headingAnchor" id="H50944073"><span class="h2">Ineffective</span><span class="headingEndMark"> — </span>Therapies with no proven clinical benefit for improving symptoms of claudication and that thus are not recommended [<a href="#rid7">7,111</a>] include anticoagulants (eg, <a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">warfarin</a>, low-molecular-weight heparin) [<a href="#rid156">156</a>], hormone replacement therapy [<a href="#rid157">157-159</a>], <em>Ginkgo biloba </em>[<a href="#rid7">7,36,160,161</a>], Padma 28 [<a href="#rid2">2,7,36,162</a>], garlic [<a href="#rid163">163</a>], and <a class="drug drug_general" data-topicid="10049" href="/z/d/drug information/10049.html" rel="external">vitamin E</a> supplementation [<a href="#rid7">7,164</a>]. Chelation therapy also does not improve claudication distance in PAD [<a href="#rid7">7,165</a>]. </p><p class="headingAnchor" id="H50944085"><span class="h2">Investigational</span><span class="headingEndMark"> — </span>Pharmacologic and device therapies (eg, negative pressure wound therapy) under investigation for the treatment of symptoms of peripheral artery disease are reviewed separately. (See  <a class="medical medical_review" href="/z/d/html/94161.html" rel="external">"Investigational therapies for treating symptoms of lower extremity peripheral artery disease"</a>.) </p><p class="headingAnchor" id="H50934672"><span class="h1">ONGOING EVALUATION AND FOLLOW-UP</span><span class="headingEndMark"> — </span>After initial counseling, follow-up should be scheduled at three months to assess risk reduction strategies and the effectiveness of exercise therapy and medical therapies for reducing symptoms  (<a class="graphic graphic_algorithm graphicRef109428" href="/z/d/graphic/109428.html" rel="external">algorithm 1</a>) [<a href="#rid2">2</a>]. </p><p>Patients who show improvement and who are satisfied with their progress can be scheduled for annual vascular examination, which should include ankle-brachial index testing. In the interim, repeat noninvasive vascular studies are not needed unless there is a significant change in symptoms [<a href="#rid166">166</a>]. </p><p class="headingAnchor" id="H53753243"><span class="h2">Referral for possible intervention</span><span class="headingEndMark"> — </span>If the patient has been compliant with risk reduction strategies, yet six months to one year of exercise therapy and adjunctive pharmacotherapy have failed to provide satisfactory improvement, referral for possible intervention can be suggested  (<a class="graphic graphic_algorithm graphicRef109428" href="/z/d/graphic/109428.html" rel="external">algorithm 1</a>). (See  <a class="medical medical_review" href="/z/d/html/15220.html" rel="external">"Approach to revascularization for claudication due to peripheral artery disease", section on 'Clinical criteria for revascularization'</a>.)</p><p>Noncompliance, particularly continued smoking, remains a significant issue in treating patients with peripheral artery disease (PAD) [<a href="#rid167">167</a>]. Those who continue to smoke should be counseled again of the increased risk for PAD progression [<a href="#rid44">44</a>]. Most vascular practitioners are generally reluctant to suggest intervention (open or percutaneous) in patients with claudication who continue to smoke because of overall worse outcomes. </p><p class="headingAnchor" id="H2836633703"><span class="h2">Interventions for claudication</span><span class="headingEndMark"> — </span>Options for intervention include percutaneous intervention, surgical bypass, or a combination of these (hybrid procedure). </p><p class="bulletIndent1"><span class="glyph">●</span>Percutaneous intervention involves accessing typically the femoral artery with an arterial sheath and passing various wires or catheters to guide the placement of an expandable balloon and/or stent, or other devices. Balloon angioplasty results in a "controlled" dissection of the arterial media, widening the lumen of the stenosed vessel. Adjunctive stenting may be needed if the vessel does not remain patent or the dissection progresses. (See  <a class="medical medical_review" href="/z/d/html/15217.html" rel="external">"Endovascular techniques for lower extremity revascularization"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Surgical revascularization involves identifying an appropriate vessel above and another below the arterial obstruction onto which to suture a graft to bypass the obstruction. The graft can be autogenous vein or prosthetic material. (See  <a class="medical medical_review" href="/z/d/html/15194.html" rel="external">"Lower extremity surgical bypass techniques"</a>.)</p><p></p><p>Determining whether percutaneous or surgical revascularization is the more appropriate initial intervention for patients with claudication depends upon the location and extent of disease and the patient's risk for the intervention, among other factors  (<a class="graphic graphic_algorithm graphicRef109428" href="/z/d/graphic/109428.html" rel="external">algorithm 1</a>). Vascular imaging is used to define vascular anatomy to plan intervention. (See  <a class="medical medical_review" href="/z/d/html/8201.html" rel="external">"Noninvasive diagnosis of upper and lower extremity arterial disease", section on 'Duplex ultrasound'</a> and  <a class="medical medical_review" href="/z/d/html/101673.html" rel="external">"Advanced vascular imaging for lower extremity peripheral artery disease"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span>Aortoiliac disease – Aortoiliac disease is also called inflow disease. Claudication resulting from disease in this location often tends to be more disabling (buttock or thigh claudication), and the threshold to intervene when treating claudication for inflow disease is generally lower than for more distal disease  (<a class="graphic graphic_algorithm graphicRef109428" href="/z/d/graphic/109428.html" rel="external">algorithm 1</a>). Options for treating aortoiliac disease include iliac artery angioplasty and stenting, aortoiliac bypass, and aortofemoral bypass, among others. (See  <a class="medical medical_review" href="/z/d/html/15220.html" rel="external">"Approach to revascularization for claudication due to peripheral artery disease", section on 'Revascularization to restore inflow'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Femoropopliteal disease – Disease below the inguinal ligament is also called outflow disease. Calf claudication is usually due to a lesion in the superficial femoral or popliteal artery and can be treated using balloon angioplasty/stenting of the femoral or superficial femoral artery, or surgical bypass such as femoral to above-knee popliteal bypass or femoral to below-knee bypass. Rarely, a more distal bypass may be needed to treat symptoms of claudication. (See  <a class="medical medical_review" href="/z/d/html/15220.html" rel="external">"Approach to revascularization for claudication due to peripheral artery disease", section on 'Infrainguinal revascularization'</a>.)</p><p></p><p class="headingAnchor" id="H881748518"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/117201.html" rel="external">"Society guideline links: Occlusive carotid, aortic, renal, mesenteric, and peripheral atherosclerotic disease"</a>.)</p><p class="headingAnchor" id="H39"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/z/d/html/15738.html" rel="external">"Patient education: Peripheral artery disease and claudication (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/z/d/html/3426.html" rel="external">"Patient education: Peripheral artery disease and claudication (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H2548711518"><span class="h1">PATIENT PERSPECTIVE TOPIC</span><span class="headingEndMark"> — </span>Patient perspectives are provided for selected disorders to help clinicians better understand the patient experience and patient concerns. These narratives may offer insights into patient values and preferences not included in other UpToDate topics. (See  <a class="medical medical_review" href="/z/d/html/134944.html" rel="external">"Patient perspective: Peripheral artery disease"</a>.)</p><p class="headingAnchor" id="H40"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Approach to management</strong> – Management of patients with claudication due to atherosclerotic disease is aimed at lowering the risk of cardiovascular disease progression and complications and improving claudication symptoms. For most patients with claudication, we recommend an initial medical treatment regimen that includes risk reduction, exercise therapy (for those who can participate), and possibly pharmacologic therapy, rather than initial vascular intervention (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Symptoms of claudication are associated with a low risk of progression to limb-threatening lower extremity ischemia, and a major concern with intervention is that some patients may suffer complications that worsen their symptoms. A subset of patients with debilitating claudication and inflow disease may benefit from early vascular intervention. (See <a class="local">'Approach to management'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Risk factor modification</strong> – Claudication is associated with an increased risk of coronary, cerebrovascular, and renovascular disease, and peripheral artery disease (PAD) is a coronary heart disease risk equivalent. To reduce the risk for cardiovascular disease progression and complications, we recommend a secondary prevention strategy that includes antiplatelet therapy (<a class="drug drug_general" data-topicid="8907" href="/z/d/drug information/8907.html" rel="external">aspirin</a> 75 to 162 mg/day or <a class="drug drug_general" data-topicid="8921" href="/z/d/drug information/8921.html" rel="external">clopidogrel</a> 75 mg/day), smoking cessation, control of blood sugar and blood pressure, lipid-lowering therapy, and dietary modification (as needed) to achieve the goals set in national guidelines. (See <a class="local">'Risk for progression and risk modification'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supervised exercise therapy</strong> – For patients who can participate in exercise therapy, we suggest supervised rather than unsupervised exercise therapy, where available (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). The value of an unsupervised exercise program is less well studied but can still generally be recommended for patients who cannot participate in a supervised exercise program. Exercise therapy should follow a high-intensity regimen and be performed for a minimum of 30 to 45 minutes at least three times per week for a minimum of 12 weeks prior to reevaluation. During each session, an exercise level that is of sufficient intensity to elicit claudication should be achieved. (See <a class="local">'Exercise therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Pharmacologic therapy</strong> – For most patients with lifestyle-limiting claudication who do not have an improvement in symptoms with risk modification and exercise therapy, we suggest a therapeutic trial of naftidrofuryl or <a class="drug drug_general" data-topicid="8872" href="/z/d/drug information/8872.html" rel="external">cilostazol</a> (100 mg twice daily) depending upon availability (<a class="grade" href="https:///uptodate/show/grade_5" rel="external">Grade 2B</a>). Naftidrofuryl has fewer side effects, and, where both are available, naftidrofuryl can be tried first. If the effect is not sufficient, then changing to cilostazol is appropriate. (See <a class="local">'Pharmacologic therapy to improve walking'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Follow-up</strong> – We suggest follow-up after three months to assess the effectiveness of the initial medical therapy regimen for improving symptoms. (See <a class="local">'Ongoing evaluation and follow-up'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients who show improvement and who are satisfied with their progress can be scheduled for annual vascular examination. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For patients who have been compliant with risk reduction strategies, yet six months to one year of exercise therapy and adjunctive pharmacotherapy have failed to provide satisfactory improvement, referral for possible revascularization is appropriate. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Options for revascularization include percutaneous intervention, surgical bypass, or a combination of these, and the choice depends upon the level of obstruction (aortoiliac, femoropopliteal) and severity of disease, and the patient's risk for the intervention. </p><p></p><p class="headingAnchor" id="H1189035645"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Emile R Mohler, III, MD (deceased), who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Bailey SR, Beckman JA, Dao TD, et al. ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine. J Am Coll Cardiol 2019; 73:214.</a></li><li><a class="nounderline abstract_t">Society for Vascular Surgery Lower Extremity Guidelines Writing Group, Conte MS, Pomposelli FB, et al. Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication. J Vasc Surg 2015; 61:2S.</a></li><li><a class="nounderline abstract_t">Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135:e726.</a></li><li><a class="nounderline abstract_t">Golledge J, Moxon JV, Rowbotham S, et al. Risk of major amputation in patients with intermittent claudication undergoing early revascularization. Br J Surg 2018; 105:699.</a></li><li><a class="nounderline abstract_t">Mazari FA, Khan JA, Carradice D, et al. Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise or combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg 2013; 100:1172.</a></li><li><a class="nounderline abstract_t">van Reijen NS, van Dieren S, Frans FA, et al. Cost Effectiveness of Endovascular Revascularisation vs. Exercise Therapy for Intermittent Claudication Due to Iliac Artery Obstruction. Eur J Vasc Endovasc Surg 2022; 63:430.</a></li><li><a class="nounderline abstract_t">Hirsch AT, Haskal ZJ, Hertzer NR, et al. ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation. Circulation 2006; 113:e463.</a></li><li><a class="nounderline abstract_t">Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study. J Am Coll Cardiol 2015; 65:999.</a></li><li><a class="nounderline abstract_t">Murphy TP, Cutlip DE, Regensteiner JG, et al. Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study. Circulation 2012; 125:130.</a></li><li><a class="nounderline abstract_t">Fakhry F, Spronk S, van der Laan L, et al. Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial. JAMA 2015; 314:1936.</a></li><li><a class="nounderline abstract_t">Fakhry F, Fokkenrood HJ, Spronk S, et al. Endovascular revascularisation versus conservative management for intermittent claudication. Cochrane Database Syst Rev 2018; 3:CD010512.</a></li><li><a class="nounderline abstract_t">Pandey A, Banerjee S, Ngo C, et al. Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv 2017; 10:712.</a></li><li><a class="nounderline abstract_t">Koelemay MJW, van Reijen NS, van Dieren S, et al. Editor's Choice - Randomised Clinical Trial of Supervised Exercise Therapy vs. Endovascular Revascularisation for Intermittent Claudication Caused by Iliac Artery Obstruction: The SUPER study. Eur J Vasc Endovasc Surg 2022; 63:421.</a></li><li><a class="nounderline abstract_t">Lindgren HIV, Qvarfordt P, Bergman S, et al. Primary Stenting of the Superficial Femoral Artery in Patients with Intermittent Claudication Has Durable Effects on Health-Related Quality of Life at 24 Months: Results of a Randomized Controlled Trial. Cardiovasc Intervent Radiol 2018; 41:872.</a></li><li><a class="nounderline abstract_t">Parmenter BJ, Dieberg G, Phipps G, Smart NA. Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis. Vasc Med 2015; 20:30.</a></li><li><a class="nounderline abstract_t">Nordanstig J, Taft C, Hensäter M, et al. Two-year results from a randomized clinical trial of revascularization in patients with intermittent claudication. Br J Surg 2016; 103:1290.</a></li><li><a class="nounderline abstract_t">Nordanstig J, Taft C, Hensäter M, et al. Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial. Circulation 2014; 130:939.</a></li><li><a class="nounderline abstract_t">Thanigaimani S, Phie J, Sharma C, et al. Network Meta-Analysis Comparing the Outcomes of Treatments for Intermittent Claudication Tested in Randomized Controlled Trials. J Am Heart Assoc 2021; 10:e019672.</a></li><li><a class="nounderline abstract_t">Fakhry F, Rouwet EV, den Hoed PT, et al. Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial. Br J Surg 2013; 100:1164.</a></li><li><a class="nounderline abstract_t">Creasy TS, McMillan PJ, Fletcher EW, et al. Is percutaneous transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective randomised trial. Eur J Vasc Surg 1990; 4:135.</a></li><li><a class="nounderline abstract_t">Mazari FA, Gulati S, Rahman MN, et al. Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication. Ann Vasc Surg 2010; 24:69.</a></li><li><a class="nounderline abstract_t">Perkins JM, Collin J, Creasy TS, et al. Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial. Eur J Vasc Endovasc Surg 1996; 11:409.</a></li><li><a class="nounderline abstract_t">Hobbs SD, Marshall T, Fegan C, et al. The constitutive procoagulant and hypofibrinolytic state in patients with intermittent claudication due to infrainguinal disease significantly improves with percutaneous transluminal balloon angioplasty. J Vasc Surg 2006; 43:40.</a></li><li><a class="nounderline abstract_t">Hobbs SD, Bradbury AW. The EXercise versus Angioplasty in Claudication Trial (EXACT): reasons for recruitment failure and the implications for research into and treatment of intermittent claudication. J Vasc Surg 2006; 44:432.</a></li><li><a class="nounderline abstract_t">Spronk S, Bosch JL, den Hoed PT, et al. Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based exercise training--randomized controlled trial. Radiology 2009; 250:586.</a></li><li><a class="nounderline abstract_t">Mazari FA, Khan JA, Samuel N, et al. Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease. Br J Surg 2017; 104:76.</a></li><li><a class="nounderline abstract_t">Mazari FA, Khan JA, Carradice D, et al. Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermittent claudication due to femoropopliteal arterial disease. Br J Surg 2012; 99:39.</a></li><li><a class="nounderline abstract_t">Gelin J, Jivegård L, Taft C, et al. Treatment efficacy of intermittent claudication by surgical intervention, supervised physical exercise training compared to no treatment in unselected randomised patients I: one year results of functional and physiological improvements. Eur J Vasc Endovasc Surg 2001; 22:107.</a></li><li><a class="nounderline abstract_t">Nylaende M, Abdelnoor M, Stranden E, et al. The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication. Eur J Vasc Endovasc Surg 2007; 33:3.</a></li><li><a class="nounderline abstract_t">Nylaende M, Kroese AJ, Morken B, et al. Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study. Vasc Med 2007; 12:275.</a></li><li><a class="nounderline abstract_t">Whyman MR, Fowkes FG, Kerracher EM, et al. Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial. J Vasc Surg 1997; 26:551.</a></li><li><a class="nounderline abstract_t">Whyman MR, Fowkes FG, Kerracher EM, et al. Randomised controlled trial of percutaneous transluminal angioplasty for intermittent claudication. Eur J Vasc Endovasc Surg 1996; 12:167.</a></li><li><a class="nounderline abstract_t">Greenhalgh RM, Belch JJ, Brown LC, et al. The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease. Eur J Vasc Endovasc Surg 2008; 36:680.</a></li><li><a class="nounderline abstract_t">Djerf H, Millinger J, Falkenberg M, et al. Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial. Circ Cardiovasc Interv 2020; 13:e008450.</a></li><li><a class="nounderline abstract_t">Aboyans V, Ricco JB, Bartelink MEL, et al. 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS). Eur Heart J 2018; 39:763.</a></li><li><a class="nounderline abstract_t">2011 WRITING GROUP MEMBERS, 2005 WRITING COMMITTEE MEMBERS, ACCF/AHA TASK FORCE MEMBERS. 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation 2011; 124:2020.</a></li><li><a class="nounderline abstract_t">European Stroke Organisation, Tendera M, Aboyans V, et al. ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). Eur Heart J 2011; 32:2851.</a></li><li><a class="nounderline abstract_t">Norgren L, Hiatt WR, Dormandy JA, et al. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007; 45 Suppl S:S5.</a></li><li><a class="nounderline abstract_t">Smith SC Jr, Benjamin EJ, Bonow RO, et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association. J Am Coll Cardiol 2011; 58:2432.</a></li><li><a class="nounderline abstract_t">Nicolaï SP, Hendriks EJ, Prins MH, et al. Optimizing supervised exercise therapy for patients with intermittent claudication. J Vasc Surg 2010; 52:1226.</a></li><li><a class="nounderline abstract_t">Girolami B, Bernardi E, Prins MH, et al. Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis. Arch Intern Med 1999; 159:337.</a></li><li><a class="nounderline abstract_t">Ameli FM, Stein M, Provan JL, Prosser R. The effect of postoperative smoking on femoropopliteal bypass grafts. Ann Vasc Surg 1989; 3:20.</a></li><li><a class="nounderline abstract_t">Quick CR, Cotton LT. The measured effect of stopping smoking on intermittent claudication. Br J Surg 1982; 69 Suppl:S24.</a></li><li><a class="nounderline abstract_t">Jonason T, Bergström R. Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality. Acta Med Scand 1987; 221:253.</a></li><li><a class="nounderline abstract_t">Watson L, Ellis B, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2008; :CD000990.</a></li><li><a class="nounderline abstract_t">Vemulapalli S, Dolor RJ, Hasselblad V, et al. Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis. Am Heart J 2015; 169:924.</a></li><li><a class="nounderline abstract_t">Hageman D, Fokkenrood HJ, Gommans LN, et al. Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication. Cochrane Database Syst Rev 2018; 4:CD005263.</a></li><li><a class="nounderline abstract_t">Kruidenier LM, Nicolaï SP, Hendriks EJ, et al. Supervised exercise therapy for intermittent claudication in daily practice. J Vasc Surg 2009; 49:363.</a></li><li><a class="nounderline abstract_t">McDermott MM, Liu K, Guralnik JM, et al. Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial. JAMA 2013; 310:57.</a></li><li><a class="nounderline abstract_t">Makris GC, Lattimer CR, Lavida A, Geroulakos G. Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease. Eur J Vasc Endovasc Surg 2012; 44:569.</a></li><li><a class="nounderline abstract_t">Al-Jundi W, Madbak K, Beard JD, et al. Systematic review of home-based exercise programmes for individuals with intermittent claudication. Eur J Vasc Endovasc Surg 2013; 46:690.</a></li><li><a class="nounderline abstract_t">Cunningham MA, Swanson V, O'Carroll RE, Holdsworth RJ. Randomized clinical trial of a brief psychological intervention to increase walking in patients with intermittent claudication. Br J Surg 2012; 99:49.</a></li><li><a class="nounderline abstract_t">van Asselt AD, Nicolaï SP, Joore MA, et al. Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice. Eur J Vasc Endovasc Surg 2011; 41:97.</a></li><li><a class="nounderline abstract_t">Gardner AW, Parker DE, Montgomery PS, et al. Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial. Circulation 2011; 123:491.</a></li><li><a class="nounderline abstract_t">Jansen SCP, van Nistelrooij LPJ, Scheltinga MRM, et al. Successful Implementation of the Exercise First Approach for Intermittent Claudication in the Netherlands is Associated with Few Lower Limb Revascularisations. Eur J Vasc Endovasc Surg 2020; 60:881.</a></li><li><a class="nounderline abstract_t">Brendle DC, Joseph LJ, Corretti MC, et al. Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease. Am J Cardiol 2001; 87:324.</a></li><li><a class="nounderline abstract_t">McDermott MM, Liu K, Ferrucci L, et al. Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more. Ann Intern Med 2006; 144:10.</a></li><li><a class="nounderline abstract_t">Tisi PV, Shearman CP. The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking? Eur J Vasc Endovasc Surg 1998; 15:7.</a></li><li><a class="nounderline abstract_t">Gustafsson T, Kraus WE. Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology. Front Biosci 2001; 6:D75.</a></li><li><a class="nounderline abstract_t">Hiatt WR, Regensteiner JG, Wolfel EE, et al. Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease. J Appl Physiol (1985) 1996; 81:780.</a></li><li><a class="nounderline abstract_t">Ernst EE, Matrai A. Intermittent claudication, exercise, and blood rheology. Circulation 1987; 76:1110.</a></li><li><a class="nounderline abstract_t">Harwood AE, Cayton T, Sarvanandan R, et al. A Review of the Potential Local Mechanisms by Which Exercise Improves Functional Outcomes in Intermittent Claudication. Ann Vasc Surg 2016; 30:312.</a></li><li><a class="nounderline abstract_t">Parmenter BJ, Dieberg G, Smart NA. Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis. Sports Med 2015; 45:231.</a></li><li><a class="nounderline abstract_t">Lane R, Harwood A, Watson L, Leng GC. Exercise for intermittent claudication. Cochrane Database Syst Rev 2017; 12:CD000990.</a></li><li><a class="nounderline abstract_t">van den Houten MML, Hageman D, Gommans LNM, et al. The Effect of Supervised Exercise, Home Based Exercise and Endovascular Revascularisation on Physical Activity in Patients With Intermittent Claudication: A Network Meta-analysis. Eur J Vasc Endovasc Surg 2019; 58:383.</a></li><li><a class="nounderline abstract_t">Garg PK, Tian L, Criqui MH, et al. Physical activity during daily life and mortality in patients with peripheral arterial disease. Circulation 2006; 114:242.</a></li><li><a class="nounderline abstract_t">Morris DR, Rodriguez AJ, Moxon JV, et al. Association of lower extremity performance with cardiovascular and all-cause mortality in patients with peripheral artery disease: a systematic review and meta-analysis. J Am Heart Assoc 2014; 3.</a></li><li><a class="nounderline abstract_t">Jansen SCP, Hoorweg BBN, Hoeks SE, et al. A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication. J Vasc Surg 2019; 69:1293.</a></li><li><a class="nounderline abstract_t">McDermott MM, Criqui MH, Greenland P, et al. Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance. J Vasc Surg 2004; 39:523.</a></li><li><a class="nounderline abstract_t">Harwood AE, Pymer S, Ingle L, et al. Exercise training for intermittent claudication: a narrative review and summary of guidelines for practitioners. BMJ Open Sport Exerc Med 2020; 6:e000897.</a></li><li><a class="nounderline abstract_t">Gardner AW, Montgomery PS, Parker DE. Optimal exercise program length for patients with claudication. J Vasc Surg 2012; 55:1346.</a></li><li><a class="nounderline abstract_t">Fakhry F, van de Luijtgaarden KM, Bax L, et al. Supervised walking therapy in patients with intermittent claudication. J Vasc Surg 2012; 56:1132.</a></li><li><a class="nounderline abstract_t">Treat-Jacobson D, McDermott MM, Bronas UG, et al. Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association. Circulation 2019; 139:e10.</a></li><li><a class="nounderline abstract_t">Gerhard-Herman MD, Gornik HL, Barrett C, et al. 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation 2017; 135:e686.</a></li><li><a class="nounderline abstract_t">Sanderson B, Askew C, Stewart I, et al. Short-term effects of cycle and treadmill training on exercise tolerance in peripheral arterial disease. J Vasc Surg 2006; 44:119.</a></li><li><a class="nounderline abstract_t">Szymczak M, Oszkinis G, Majchrzycki M. The Impact of Walking Exercises and Resistance Training upon the Walking Distance in Patients with Chronic Lower Limb Ischaemia. Biomed Res Int 2016; 2016:7515238.</a></li><li><a class="nounderline abstract_t">Delaney CL, Miller MD, Allan RB, Spark JI. The impact of different supervised exercise regimens on endothelial function in patients with intermittent claudication. Vascular 2015; 23:561.</a></li><li><a class="nounderline abstract_t">Collins EG, McBurney C, Butler J, et al. The Effects of Walking or Walking-with-Poles Training on Tissue Oxygenation in Patients with Peripheral Arterial Disease. Int J Vasc Med 2012; 2012:985025.</a></li><li><a class="nounderline abstract_t">Bulińska K, Kropielnicka K, Jasiński T, et al. Nordic pole walking improves walking capacity in patients with intermittent claudication: a randomized controlled trial. Disabil Rehabil 2016; 38:1318.</a></li><li><a class="nounderline abstract_t">Kropielnicka K, Dziubek W, Bulińska K, et al. Influence of the Physical Training on Muscle Function and Walking Distance in Symptomatic Peripheral Arterial Disease in Elderly. Biomed Res Int 2018; 2018:1937527.</a></li><li><a class="nounderline abstract_t">Treat-Jacobson D, Bronas UG, Leon AS. Efficacy of arm-ergometry versus treadmill exercise training to improve walking distance in patients with claudication. Vasc Med 2009; 14:203.</a></li><li><a class="nounderline abstract_t">McDermott MM, Ades P, Guralnik JM, et al. Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial. JAMA 2009; 301:165.</a></li><li><a class="nounderline abstract_t">Ritti-Dias RM, Wolosker N, de Moraes Forjaz CL, et al. Strength training increases walking tolerance in intermittent claudication patients: randomized trial. J Vasc Surg 2010; 51:89.</a></li><li><a class="nounderline abstract_t">Regensteiner JG, Steiner JF, Hiatt WR. Exercise training improves functional status in patients with peripheral arterial disease. J Vasc Surg 1996; 23:104.</a></li><li><a class="nounderline abstract_t">Saxton JM, Zwierska I, Blagojevic M, et al. Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic peripheral arterial disease. J Vasc Surg 2011; 53:1265.</a></li><li><a class="nounderline abstract_t">Bronas UG, Treat-Jacobson D, Leon AS. Comparison of the effect of upper body-ergometry aerobic training vs treadmill training on central cardiorespiratory improvement and walking distance in patients with claudication. J Vasc Surg 2011; 53:1557.</a></li><li><a class="nounderline abstract_t">Zwierska I, Walker RD, Choksy SA, et al. Upper- vs lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: a randomized controlled trial. J Vasc Surg 2005; 42:1122.</a></li><li><a class="nounderline abstract_t">Grizzo Cucato G, de Moraes Forjaz CL, Kanegusuku H, et al. Effects of walking and strength training on resting and exercise cardiovascular responses in patients with intermittent claudication. Vasa 2011; 40:390.</a></li><li><a class="nounderline abstract_t">Hiatt WR, Wolfel EE, Meier RH, Regensteiner JG. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 1994; 90:1866.</a></li><li><a class="nounderline abstract_t">Wang E, Helgerud J, Loe H, et al. Maximal strength training improves walking performance in peripheral arterial disease patients. Scand J Med Sci Sports 2010; 20:764.</a></li><li><a class="nounderline abstract_t">Lima A, Ritti-Dias R, Forjaz CL, et al. A session of resistance exercise increases vasodilation in intermittent claudication patients. Appl Physiol Nutr Metab 2015; 40:59.</a></li><li><a class="nounderline abstract_t">Mosti MP, Wang E, Wiggen ØN, et al. Concurrent strength and endurance training improves physical capacity in patients with peripheral arterial disease. Scand J Med Sci Sports 2011; 21:e308.</a></li><li><a class="nounderline abstract_t">Jansen SC, Abaraogu UO, Lauret GJ, et al. Modes of exercise training for intermittent claudication. Cochrane Database Syst Rev 2020; 8:CD009638.</a></li><li><a class="nounderline abstract_t">Parmenter BJ, Raymond J, Dinnen P, Singh MA. A systematic review of randomized controlled trials: Walking versus alternative exercise prescription as treatment for intermittent claudication. Atherosclerosis 2011; 218:1.</a></li><li><a class="nounderline abstract_t">Gommans LN, Saarloos R, Scheltinga MR, et al. Editor's choice--The effect of supervision on walking distance in patients with intermittent claudication: a meta-analysis. Eur J Vasc Endovasc Surg 2014; 48:169.</a></li><li><a class="nounderline abstract_t">Gardner AW, Poehlman ET. Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis. JAMA 1995; 274:975.</a></li><li><a class="nounderline abstract_t">Gardner AW, Montgomery PS, Flinn WR, Katzel LI. The effect of exercise intensity on the response to exercise rehabilitation in patients with intermittent claudication. J Vasc Surg 2005; 42:702.</a></li><li><a class="nounderline abstract_t">McDermott MM, Spring B, Tian L, et al. Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease: The LITE Randomized Clinical Trial. JAMA 2021; 325:1266.</a></li><li><a class="nounderline abstract_t">Menêses AL, de Lima GH, Forjaz CL, et al. Impact of a supervised strength training or walking training over a subsequent unsupervised therapy period on walking capacity in patients with claudication. J Vasc Nurs 2011; 29:81.</a></li><li><a class="nounderline abstract_t">Fokkenrood HJ, Bendermacher BL, Lauret GJ, et al. Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication. Cochrane Database Syst Rev 2013; :CD005263.</a></li><li><a class="nounderline abstract_t">Li Y, Li Z, Chang G, et al. Effect of structured home-based exercise on walking ability in patients with peripheral arterial disease: a meta-analysis. Ann Vasc Surg 2015; 29:597.</a></li><li><a class="nounderline abstract_t">McDermott MM, Guralnik JM, Criqui MH, et al. Unsupervised exercise and mobility loss in peripheral artery disease: a randomized controlled trial. J Am Heart Assoc 2015; 4.</a></li><li><a class="nounderline abstract_t">Harwood AE, Smith GE, Cayton T, et al. A Systematic Review of the Uptake and Adherence Rates to Supervised Exercise Programs in Patients with Intermittent Claudication. Ann Vasc Surg 2016; 34:280.</a></li><li><a class="nounderline abstract_t">Golledge J, Singh TP, Alahakoon C, et al. Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease. Br J Surg 2019; 106:319.</a></li><li><a class="nounderline abstract_t">Cornelis N, Nassen J, Buys R, et al. The Impact of Supervised Exercise Training on Traditional Cardiovascular Risk Factors in Patients With Intermittent Claudication: A Systematic Review and Meta-Analysis. Eur J Vasc Endovasc Surg 2019; 58:75.</a></li><li><a class="nounderline abstract_t">Saratzis A, Paraskevopoulos I, Patel S, et al. Supervised Exercise Therapy and Revascularization for Intermittent Claudication: Network Meta-Analysis of Randomized Controlled Trials. JACC Cardiovasc Interv 2019; 12:1125.</a></li><li><a class="nounderline abstract_t">Nicolaï SP, Teijink JA, Prins MH, Exercise Therapy in Peripheral Arterial Disease Study Group. Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication. J Vasc Surg 2010; 52:348.</a></li><li><a class="nounderline abstract_t">McDermott MM, Spring B, Berger JS, et al. Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial. JAMA 2018; 319:1665.</a></li><li class="breakAll">https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=287&amp;NcaName=Supervised+Exercise+Therapy+(SET)+for+Symptomatic+Peripheral+Artery+Disease+(PAD)&amp;ExpandComments=y&amp;CommentPeriod=0&amp;bc=gCAAAAAACAAAAA%3d%3d&amp; https://www.cms.gov/medicare-coverage-database/shared/handlers/highwire.ashx?url=https://www.cms.gov/medicare-coverage-database/details/nca-proposed-decision-memo.aspx@@@NCAId$$$287&amp;session=1cin1p45wtawuf3p0uukf4fn&amp;kq=873007742 (Accessed on May 31, 2017).</li><li><a class="nounderline abstract_t">Alonso-Coello P, Bellmunt S, McGorrian C, et al. Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141:e669S.</a></li><li><a class="nounderline abstract_t">Sobel M, Verhaeghe R. Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133:815S.</a></li><li><a class="nounderline abstract_t">Reilly MP, Mohler ER 3rd. Cilostazol: treatment of intermittent claudication. Ann Pharmacother 2001; 35:48.</a></li><li><a class="nounderline abstract_t">Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med 1999; 159:2041.</a></li><li><a class="nounderline abstract_t">O'Donnell ME, Badger SA, Sharif MA, et al. The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease. J Vasc Surg 2009; 49:1226.</a></li><li><a class="nounderline abstract_t">Drugs for intermittent claudication. Med Lett Drugs Ther 2004; 46:13.</a></li><li><a class="nounderline abstract_t">Wilhite DB, Comerota AJ, Schmieder FA, et al. Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time. J Vasc Surg 2003; 38:710.</a></li><li><a class="nounderline abstract_t">Dawson DL, Cutler BS, Meissner MH, Strandness DE Jr. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998; 98:678.</a></li><li><a class="nounderline abstract_t">Money SR, Herd JA, Isaacsohn JL, et al. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease. J Vasc Surg 1998; 27:267.</a></li><li><a class="nounderline abstract_t">Regensteiner JG, Ware JE Jr, McCarthy WJ, et al. Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials. J Am Geriatr Soc 2002; 50:1939.</a></li><li><a class="nounderline abstract_t">Thompson PD, Zimet R, Forbes WP, Zhang P. Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication. Am J Cardiol 2002; 90:1314.</a></li><li><a class="nounderline abstract_t">Pande RL, Hiatt WR, Zhang P, et al. A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication. Vasc Med 2010; 15:181.</a></li><li><a class="nounderline abstract_t">Stevens JW, Simpson E, Harnan S, et al. Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication. Br J Surg 2012; 99:1630.</a></li><li><a class="nounderline abstract_t">Bedenis R, Stewart M, Cleanthis M, et al. Cilostazol for intermittent claudication. Cochrane Database Syst Rev 2014; :CD003748.</a></li><li><a class="nounderline abstract_t">Lehert P, Comte S, Gamand S, Brown TM. Naftidrofuryl in intermittent claudication: a retrospective analysis. J Cardiovasc Pharmacol 1994; 23 Suppl 3:S48.</a></li><li><a class="nounderline abstract_t">Moody AP, al-Khaffaf HS, Lehert P, et al. An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl. J Cardiovasc Pharmacol 1994; 23 Suppl 3:S44.</a></li><li><a class="nounderline abstract_t">Jung F, Kiesewetter H, Mrowietz C, et al. Hemorrheological, micro- and macrocirculatory effects of naftidrofuryl in an acute study: a randomized, placebo-controlled, double-blind individual comparison. Int J Clin Pharmacol Ther Toxicol 1987; 25:507.</a></li><li><a class="nounderline abstract_t">de Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2012; 12:CD001368.</a></li><li><a class="nounderline abstract_t">Aung PP, Maxwell HG, Jepson RG, et al. Lipid-lowering for peripheral arterial disease of the lower limb. Cochrane Database Syst Rev 2007; :CD000123.</a></li><li><a class="nounderline abstract_t">Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation 2003; 108:1481.</a></li><li><a class="nounderline abstract_t">Aronow WS, Nayak D, Woodworth S, Ahn C. Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol 2003; 92:711.</a></li><li><a class="nounderline abstract_t">Mondillo S, Ballo P, Barbati R, et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med 2003; 114:359.</a></li><li><a class="nounderline abstract_t">de Groot E, Jukema JW, Montauban van Swijndregt AD, et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998; 31:1561.</a></li><li><a class="nounderline abstract_t">Barndt R Jr, Blankenhorn DH, Crawford DW, Brooks SH. Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients. Ann Intern Med 1977; 86:139.</a></li><li><a class="nounderline abstract_t">Duffield RG, Lewis B, Miller NE, et al. Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial. Lancet 1983; 2:639.</a></li><li><a class="nounderline abstract_t">Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991; 83:438.</a></li><li><a class="nounderline abstract_t">Hiatt WR, Hirsch AT, Creager MA, et al. Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease. Vasc Med 2010; 15:171.</a></li><li><a class="nounderline abstract_t">Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery 1996; 120:672.</a></li><li><a class="nounderline abstract_t">Coto V, Cocozza M, Oliviero U, et al. Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 1989; 40:880.</a></li><li><a class="nounderline abstract_t">Signorini GP, Salmistraro G, Maraglino G. Efficacy of indobufen in the treatment of intermittent claudication. Angiology 1988; 39:742.</a></li><li><a class="nounderline abstract_t">Tönnesen KH, Albuquerque P, Baitsch G, et al. Double-blind, controlled, multicenter study of indobufen versus placebo in patients with intermittent claudication. Int Angiol 1993; 12:371.</a></li><li><a class="nounderline abstract_t">Wong PF, Chong LY, Mikhailidis DP, et al. Antiplatelet agents for intermittent claudication. Cochrane Database Syst Rev 2011; :CD001272.</a></li><li><a class="nounderline abstract_t">Balsano F, Violi F. Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group. Circulation 1993; 87:1563.</a></li><li><a class="nounderline abstract_t">Arcan JC, Blanchard J, Boissel JP, et al. Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications. Angiology 1988; 39:802.</a></li><li><a class="nounderline abstract_t">Aukland A, Hurlow RA, George AJ, Stuart J. Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication. J Clin Pathol 1982; 35:740.</a></li><li><a class="nounderline abstract_t">Balsano F, Coccheri S, Libretti A, et al. Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial. J Lab Clin Med 1989; 114:84.</a></li><li><a class="nounderline abstract_t">Blanchard J, Carreras LO, Kindermans M. Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease. Nouv Rev Fr Hematol 1994; 35:523.</a></li><li><a class="nounderline abstract_t">Roekaerts F, Deleers L. Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration. Angiology 1984; 35:396.</a></li><li><a class="nounderline abstract_t">Porter JM, Cutler BS, Lee BY, et al. Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104:66.</a></li><li><a class="nounderline abstract_t">Reich T, Cutler BC, Lee BY, et al. Pentoxifylline in the treatment of intermittent claudication of the lower limbs. Angiology 1984; 35:389.</a></li><li><a class="nounderline abstract_t">Rössner M, Müller R. On the assessment of the efficacy of pentoxifylline (Trental). J Med 1987; 18:1.</a></li><li><a class="nounderline abstract_t">Hood SC, Moher D, Barber GG. Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials. CMAJ 1996; 155:1053.</a></li><li><a class="nounderline abstract_t">Salhiyyah K, Senanayake E, Abdel-Hadi M, et al. Pentoxifylline for intermittent claudication. Cochrane Database Syst Rev 2012; 1:CD005262.</a></li><li><a class="nounderline abstract_t">Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990; 81:602.</a></li><li><a class="nounderline abstract_t">Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000; 109:523.</a></li><li><a class="nounderline abstract_t">de Haro J, Acin F, Florez A, et al. A prospective randomized controlled study with intermittent mechanical compression of the calf in patients with claudication. J Vasc Surg 2010; 51:857.</a></li><li><a class="nounderline abstract_t">Cosmi B, Conti E, Coccheri S. Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication. Cochrane Database Syst Rev 2014; 2014:CD001999.</a></li><li><a class="nounderline abstract_t">Westendorp IC, in't Veld BA, Grobbee DE, et al. Hormone replacement therapy and peripheral arterial disease: the Rotterdam study. Arch Intern Med 2000; 160:2498.</a></li><li><a class="nounderline abstract_t">Hsia J, Simon JA, Lin F, et al. Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study. Circulation 2000; 102:2228.</a></li><li><a class="nounderline abstract_t">Price J, Leng GC. Steroid sex hormones for lower limb atherosclerosis. Cochrane Database Syst Rev 2012; 10:CD000188.</a></li><li><a class="nounderline abstract_t">Nicolaï SP, Kruidenier LM, Bendermacher BL, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2013; :CD006888.</a></li><li><a class="nounderline abstract_t">Nicolaï SP, Kruidenier LM, Bendermacher BL, et al. Ginkgo biloba for intermittent claudication. Cochrane Database Syst Rev 2009; :CD006888.</a></li><li><a class="nounderline abstract_t">Stewart M, Morling JR, Maxwell H. Padma 28 for intermittent claudication. Cochrane Database Syst Rev 2016; 3:CD007371.</a></li><li><a class="nounderline abstract_t">Jepson RG, Kleijnen J, Leng GC. Garlic for peripheral arterial occlusive disease. Cochrane Database Syst Rev 2013; :CD000095.</a></li><li><a class="nounderline abstract_t">Kleijnen J, Mackerras D. Vitamin E for intermittent claudication. Cochrane Database Syst Rev 2000; :CD000987.</a></li><li><a class="nounderline abstract_t">De Backer TL, Vander Stichele R, Lehert P, Van Bortel L. Naftidrofuryl for intermittent claudication. Cochrane Database Syst Rev 2008; :CD001368.</a></li><li><a class="nounderline abstract_t">American College of Cardiology Foundation(ACCF), American College of Radiology(ACR), American Institute of Ultrasound in Medicine(AIUM), et al. ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound and physiological testing: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery. J Vasc Surg 2012; 56:e17.</a></li><li><a class="nounderline abstract_t">Casillas JM, Troisgros O, Hannequin A, et al. Rehabilitation in patients with peripheral arterial disease. Ann Phys Rehabil Med 2011; 54:443.</a></li></ol></div><div id="topicVersionRevision">Topic 8210 Version 52.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30573393" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : ACC/AHA/SCAI/SIR/SVM 2018 Appropriate Use Criteria for Peripheral Artery Intervention: A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Heart Association, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, and Society for Vascular Medicine.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25638515" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Society for Vascular Surgery practice guidelines for atherosclerotic occlusive disease of the lower extremities: management of asymptomatic disease and claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840333" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29566427" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Risk of major amputation in patients with intermittent claudication undergoing early revascularization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23842831" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Economic analysis of a randomized trial of percutaneous angioplasty, supervised exercise or combined treatment for intermittent claudication due to femoropopliteal arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35148946" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cost Effectiveness of Endovascular Revascularisation vs. Exercise Therapy for Intermittent Claudication Due to Iliac Artery Obstruction.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549646" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : ACC/AHA 2005 Practice Guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease): endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation; National Heart, Lung, and Blood Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25766947" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Supervised exercise, stent revascularization, or medical therapy for claudication due to aortoiliac peripheral artery disease: the CLEVER study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22090168" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Supervised exercise versus primary stenting for claudication resulting from aortoiliac peripheral artery disease: six-month outcomes from the claudication: exercise versus endoluminal revascularization (CLEVER) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26547465" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Endovascular Revascularization and Supervised Exercise for Peripheral Artery Disease and Intermittent Claudication: A Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29518253" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Endovascular revascularisation versus conservative management for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28385410" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication: Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35151572" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Editor's Choice - Randomised Clinical Trial of Supervised Exercise Therapy vs. Endovascular Revascularisation for Intermittent Claudication Caused by Iliac Artery Obstruction: The SUPER study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29520431" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Primary Stenting of the Superficial Femoral Artery in Patients with Intermittent Claudication Has Durable Effects on Health-Related Quality of Life at 24 Months: Results of a Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25432991" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Exercise training for health-related quality of life in peripheral artery disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27220310" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Two-year results from a randomized clinical trial of revascularization in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25095886" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Improved quality of life after 1 year with an invasive versus a noninvasive treatment strategy in claudicants: one-year results of the Invasive Revascularization or Not in Intermittent Claudication (IRONIC) Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33890475" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Network Meta-Analysis Comparing the Outcomes of Treatments for Intermittent Claudication Tested in Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23842830" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Long-term clinical effectiveness of supervised exercise therapy versus endovascular revascularization for intermittent claudication from a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2140987" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Is percutaneous transluminal angioplasty better than exercise for claudication? Preliminary results from a prospective randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19762206" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Early outcomes from a randomized, controlled trial of supervised exercise, angioplasty, and combined therapy in intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8846172" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Exercise training versus angioplasty for stable claudication. Long and medium term results of a prospective, randomised trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16414385" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : The constitutive procoagulant and hypofibrinolytic state in patients with intermittent claudication due to infrainguinal disease significantly improves with percutaneous transluminal balloon angioplasty.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16890883" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The EXercise versus Angioplasty in Claudication Trial (EXACT): reasons for recruitment failure and the implications for research into and treatment of intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19188327" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Intermittent claudication: clinical effectiveness of endovascular revascularization versus supervised hospital-based exercise training--randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27763685" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Long-term outcomes of a randomized clinical trial of supervised exercise, percutaneous transluminal angioplasty or combined treatment for patients with intermittent claudication due to femoropopliteal disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22021102" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Randomized clinical trial of percutaneous transluminal angioplasty, supervised exercise and combined treatment for intermittent claudication due to femoropopliteal arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11472042" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment efficacy of intermittent claudication by surgical intervention, supervised physical exercise training compared to no treatment in unselected randomised patients I: one year results of functional and physiological improvements.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17055756" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : The Oslo balloon angioplasty versus conservative treatment study (OBACT)--the 2-years results of a single centre, prospective, randomised study in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18048463" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Beneficial effects of 1-year optimal medical treatment with and without additional PTA on inflammatory markers of atherosclerosis in patients with PAD. Results from the Oslo Balloon Angioplasty versus Conservative Treatment (OBACT) study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9357454" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Is intermittent claudication improved by percutaneous transluminal angioplasty? A randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8760978" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Randomised controlled trial of percutaneous transluminal angioplasty for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19022184" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : The adjuvant benefit of angioplasty in patients with mild to moderate intermittent claudication (MIMIC) managed by supervised exercise, smoking cessation advice and best medical therapy: results from two randomised trials for stenotic femoropopliteal and aortoiliac arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31937137" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Absence of Long-Term Benefit of Revascularization in Patients With Intermittent Claudication: Five-Year Results From the IRONIC Randomized Controlled Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28886620" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : 2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteriesEndorsed by: the European Stroke Organization (ESO)The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21959305" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21873417" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries: the Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17223489" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22055990" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation endorsed by the World Heart Federation and the Preventive Cardiovascular Nurses Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20692797" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Optimizing supervised exercise therapy for patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10030306" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Treatment of intermittent claudication with physical training, smoking cessation, pentoxifylline, or nafronyl: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2713228" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : The effect of postoperative smoking on femoropopliteal bypass grafts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7082968" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : The measured effect of stopping smoking on intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3591463" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Cessation of smoking in patients with intermittent claudication. Effects on the risk of peripheral vascular complications, myocardial infarction and mortality.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18843614" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Exercise for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26027632" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Supervised vs unsupervised exercise for intermittent claudication: A systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29627967" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Supervised exercise therapy versus home-based exercise therapy versus walking advice for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19028059" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Supervised exercise therapy for intermittent claudication in daily practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23821089" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Home-based walking exercise intervention in peripheral artery disease: a randomized clinical trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23034408" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Availability of supervised exercise programs and the role of structured home-based exercise in peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24076079" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Systematic review of home-based exercise programmes for individuals with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22038532" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Randomized clinical trial of a brief psychological intervention to increase walking in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21159527" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Cost-effectiveness of exercise therapy in patients with intermittent claudication: supervised exercise therapy versus a 'go home and walk' advice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21262997" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Efficacy of quantified home-based exercise and supervised exercise in patients with intermittent claudication: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32888779" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Successful Implementation of the Exercise First Approach for Intermittent Claudication in the Netherlands is Associated with Few Lower Limb Revascularisations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11165969" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Effects of exercise rehabilitation on endothelial reactivity in older patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16389250" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Physical performance in peripheral arterial disease: a slower rate of decline in patients who walk more.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9518994" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : The evidence for exercise-induced inflammation in intermittent claudication: should we encourage patients to stop walking?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11145922" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Exercise-induced angiogenesis-related growth and transcription factors in skeletal muscle, and their modification in muscle pathology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8872646" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Effect of exercise training on skeletal muscle histology and metabolism in peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3499255" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Intermittent claudication, exercise, and blood rheology.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26362620" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : A Review of the Potential Local Mechanisms by Which Exercise Improves Functional Outcomes in Intermittent Claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25230780" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Exercise training for management of peripheral arterial disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29278423" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Exercise for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31235306" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : The Effect of Supervised Exercise, Home Based Exercise and Endovascular Revascularisation on Physical Activity in Patients With Intermittent Claudication: A Network Meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16818814" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Physical activity during daily life and mortality in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25122666" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Association of lower extremity performance with cardiovascular and all-cause mortality in patients with peripheral artery disease: a systematic review and meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30777692" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : A systematic review and meta-analysis of the effects of supervised exercise therapy on modifiable cardiovascular risk factors in intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14981443" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Leg strength in peripheral arterial disease: associations with disease severity and lower-extremity performance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33262892" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Exercise training for intermittent claudication: a narrative review and summary of guidelines for practitioners.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22459748" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Optimal exercise program length for patients with claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23026425" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Supervised walking therapy in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30586765" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Optimal Exercise Programs for Patients With Peripheral Artery Disease: A Scientific Statement From the American Heart Association.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27840332" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : 2016 AHA/ACC Guideline on the Management of Patients With Lower Extremity Peripheral Artery Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16828435" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Short-term effects of cycle and treadmill training on exercise tolerance in peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27833919" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : The Impact of Walking Exercises and Resistance Training upon the Walking Distance in Patients with Chronic Lower Limb Ischaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25406267" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The impact of different supervised exercise regimens on endothelial function in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23050152" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : The Effects of Walking or Walking-with-Poles Training on Tissue Oxygenation in Patients with Peripheral Arterial Disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26305413" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Nordic pole walking improves walking capacity in patients with intermittent claudication: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30345295" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Influence of the Physical Training on Muscle Function and Walking Distance in Symptomatic Peripheral Arterial Disease in Elderly.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19651669" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Efficacy of arm-ergometry versus treadmill exercise training to improve walking distance in patients with claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19141764" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Treadmill exercise and resistance training in patients with peripheral arterial disease with and without intermittent claudication: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19837534" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Strength training increases walking tolerance in intermittent claudication patients: randomized trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8558725" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Exercise training improves functional status in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21215558" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Upper- versus lower-limb aerobic exercise training on health-related quality of life in patients with symptomatic peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21515017" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Comparison of the effect of upper body-ergometry aerobic training vs treadmill training on central cardiorespiratory improvement and walking distance in patients with claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16376202" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Upper- vs lower-limb aerobic exercise rehabilitation in patients with symptomatic peripheral arterial disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21948782" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Effects of walking and strength training on resting and exercise cardiovascular responses in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7923674" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19804581" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Maximal strength training improves walking performance in peripheral arterial disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25485893" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : A session of resistance exercise increases vasodilation in intermittent claudication patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21410546" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Concurrent strength and endurance training improves physical capacity in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32829481" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Modes of exercise training for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21601857" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : A systematic review of randomized controlled trials: Walking versus alternative exercise prescription as treatment for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24928167" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Editor's choice--The effect of supervision on walking distance in patients with intermittent claudication: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7674529" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Exercise rehabilitation programs for the treatment of claudication pain. A meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16242558" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : The effect of exercise intensity on the response to exercise rehabilitation in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33821898" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Effect of Low-Intensity vs High-Intensity Home-Based Walking Exercise on Walk Distance in Patients With Peripheral Artery Disease: The LITE Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21558030" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Impact of a supervised strength training or walking training over a subsequent unsupervised therapy period on walking capacity in patients with claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23970372" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Supervised exercise therapy versus non-supervised exercise therapy for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25449991" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Effect of structured home-based exercise on walking ability in patients with peripheral arterial disease: a meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25994445" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Unsupervised exercise and mobility loss in peripheral artery disease: a randomized controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27126713" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : A Systematic Review of the Uptake and Adherence Rates to Supervised Exercise Programs in Patients with Intermittent Claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30791089" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Meta-analysis of clinical trials examining the benefit of structured home exercise in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31153735" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : The Impact of Supervised Exercise Training on Traditional Cardiovascular Risk Factors in Patients With Intermittent Claudication: A Systematic Review and Meta-Analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31153838" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Supervised Exercise Therapy and Revascularization for Intermittent Claudication: Network Meta-Analysis of Randomized Controlled Trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20478681" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Multicenter randomized clinical trial of supervised exercise therapy with or without feedback versus walking advice for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710165" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29710165" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Effect of a Home-Based Exercise Intervention of Wearable Technology and Telephone Coaching on Walking Performance in Peripheral Artery Disease: The HONOR Randomized Clinical Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22315275" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Antithrombotic therapy in peripheral artery disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18574279" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Antithrombotic therapy for peripheral artery occlusive disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11197586" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Cilostazol: treatment of intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10510990" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19217745" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : The vascular and biochemical effects of cilostazol in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14973403" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Drugs for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14560218" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Managing PAD with multiple platelet inhibitors: the effect of combination therapy on bleeding time.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9715861" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9510281" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12473004" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Effect of cilostazol on treadmill walking, community-based walking ability, and health-related quality of life in patients with intermittent claudication due to peripheral arterial disease: meta-analysis of six randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12480040" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Meta-analysis of results from eight randomized, placebo-controlled trials on the effect of cilostazol on patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20385711" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : A pooled analysis of the durability and predictors of treatment response of cilostazol in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23034699" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Systematic review of the efficacy of cilostazol, naftidrofuryl oxalate and pentoxifylline for the treatment of intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25358850" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Cilostazol for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7517478" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Naftidrofuryl in intermittent claudication: a retrospective analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7517477" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : An evaluation of patients with severe intermittent claudication and the effect of treatment with naftidrofuryl.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3679623" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Hemorrheological, micro- and macrocirculatory effects of naftidrofuryl in an acute study: a randomized, placebo-controlled, double-blind individual comparison.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23235580" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Naftidrofuryl for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17943736" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Lipid-lowering for peripheral arterial disease of the lower limb.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12952839" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12972114" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12714124" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9626835" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/189658" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Regression and progression of early femoral atherosclerosis in treated hyperlipoproteinemic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6136793" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Treatment of hyperlipidaemia retards progression of symptomatic femoral atherosclerosis. A randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1991366" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Effects of colestipol-niacin therapy on human femoral atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20212073" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Effect of niacin ER/lovastatin on claudication symptoms in patients with peripheral artery disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8862377" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2679241" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Clinical efficacy of picotamide in long-term treatment of intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3048153" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Efficacy of indobufen in the treatment of intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8207316" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Double-blind, controlled, multicenter study of indobufen versus placebo in patients with intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22071801" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Antiplatelet agents for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8491012" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Effect of picotamide on the clinical progression of peripheral vascular disease. A double-blind placebo-controlled study. The ADEP Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3048155" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7047575" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2661700" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8152898" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Results of EMATAP: a double-blind placebo-controlled multicentre trial of ticlopidine in patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6380348" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Trental 400 in the treatment of intermittent claudication: results of long-term, placebo-controlled administration.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7046409" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Pentoxifylline efficacy in the treatment of intermittent claudication: multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6380347" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Pentoxifylline in the treatment of intermittent claudication of the lower limbs.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3298515" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : On the assessment of the efficacy of pentoxifylline (Trental).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8873633" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Management of intermittent claudication with pentoxifylline: meta-analysis of randomized controlled trials.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22258961" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Pentoxifylline for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2404633" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Benefit of exercise conditioning for patients with peripheral arterial disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11063952" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : A comparison of cilostazol and pentoxifylline for treating intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20347681" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : A prospective randomized controlled study with intermittent mechanical compression of the calf in patients with claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24801382" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10979062" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Hormone replacement therapy and peripheral arterial disease: the Rotterdam study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11056097" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Peripheral arterial disease in randomized trial of estrogen with progestin in women with coronary heart disease: the Heart and Estrogen/Progestin Replacement Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23076884" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Steroid sex hormones for lower limb atherosclerosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23744597" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : Ginkgo biloba for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19370657" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Ginkgo biloba for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27021597" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Padma 28 for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23633303" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : Garlic for peripheral arterial occlusive disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10796571" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Vitamin E for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18425872" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : Naftidrofuryl for intermittent claudication.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22694919" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : ACCF/ACR/AIUM/ASE/ASN/ICAVL/SCAI/SCCT/SIR/SVM/SVS 2012 appropriate use criteria for peripheral vascular ultrasound and physiological testing part I: arterial ultrasound and physiological testing: a report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American College of Radiology, American Institute of Ultrasound in Medicine, American Society of Echocardiography, American Society of Nephrology, Intersocietal Commission for the Accreditation of Vascular Laboratories, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Interventional Radiology, Society for Vascular Medicine, and Society for Vascular Surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21917541" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Rehabilitation in patients with peripheral arterial disease.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
